Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension.

Détails

ID Serval
serval:BIB_FF95D8F4D668
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension.
Périodique
Clinical Science
Auteur⸱e⸱s
Gavras H., Biollaz J., Waeber B., Brunner H.R., Gavras I., Sackel H., Charocopos F., Davies R.O.
ISSN
0143-5221
Statut éditorial
Publié
Date de publication
1981
Peer-reviewed
Oui
Volume
61
Numéro
Suppl. 7
Pages
281s-283s
Langue
anglais
Notes
Journal Article Research Support, U.S. Gov't, P.H.S. --- Old month value: Dec
Résumé
1. The effects of the new oral angiotensin-converting enzyme (ACE) inhibitor MK-421 on blood pressure, plasma renin activity, angiotensin-II, aldosterone and converting enzyme activity were assessed in 16 hypertensive patients followed for 6--18 weeks. 2. After an initial titration period, maintenance doses of 2.5--40 mg once daily produced satisfactory blood pressure control in 11 and a partial but significant decrease in the remainder. 3. Treatment was associated with no change in heart rate and no orthostatic hypotension. At 24 h after the first effective dose, blood pressure was still decreased, plasma ACE was suppressed to 16% of the baseline, plasma angiotensin to 58%, aldosterone to 42%, and plasma renin activity was elevated to 228% of the baseline. 4. Magnitude of blood pressure fall was significantly correlated with the height of pretreatment blood pressure but not with baseline levels of plasma renin activity.
Mots-clé
Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Dipeptides, Enalapril, Humans, Hypertension, Middle Aged
Pubmed
Web of science
Création de la notice
25/01/2008 11:41
Dernière modification de la notice
20/08/2019 17:29
Données d'usage